December 15, 2025

AI Models Advance Individualized Breast Cancer Recurrence Risk Assessments

Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification in early b...

The ASCO Post

December 11, 2025

Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer

Similar recurrence and regional recurrence-free survival rates were observed at 5 years with or without a sentinel lymph node biopsy in patients with clinically node-negative cT1-2 breast cancer treat...

The ASCO Post

December 11, 2025

Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy–Refractory Advanced Breast Cancers

Patients with hormone receptor–positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with the antibody-drug conjugate or standard-of-care chem...

The ASCO Post

December 09, 2025

Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS

Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering wor...

The ASCO Post

December 09, 2025

Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS

Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering wor...

The ASCO Post

December 08, 2025

Basser Center for BRCA Announces Two Award Winners

The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania has announced the recipients of its 2025 BRCA Impact Award and 2025 Basser Global Prize.

The ASCO Post

December 05, 2025

T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer

As reported in The New England Journal of Medicine by Tolaney et al, interim analysis of the phase III DESTINY-Breast09 trial has shown significantly improved progression-free survival with trastuzuma...

The ASCO Post

December 05, 2025

Memorial Sloan Kettering Names Recipients of 2025 Paul Marks Prize for Cancer Research

Memorial Sloan Kettering Cancer Center (MSK) will award three cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD...

The ASCO Post

December 05, 2025

Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction

Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treat...

The ASCO Post